Cleared Traditional

K772251 - IMMUNOGLOBULIN A NEPHEL. ASSAY

K772251 is the FDA 510(k) clearance for IMMUNOGLOBULIN A NEPHEL. ASSAY by Kallestad Laboratories, Inc.. It is a Class 2 Immunology device (product code CZP) cleared through the Traditional 510(k) pathway after a 13-day FDA review.

K772251 · Kallestad Laboratories, Inc. · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Dec 1977
Decision
13d
Days
Class 2
Risk

K772251 is an FDA 510(k) clearance for the IMMUNOGLOBULIN A NEPHEL. ASSAY. Classified as Iga, Antigen, Antiserum, Control (product code CZP), Class II - Special Controls.

Submitted by Kallestad Laboratories, Inc. (Walker, US). The FDA issued a Cleared decision on December 22, 1977 after a review of 13 days - a notably fast clearance cycle.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5510 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Kallestad Laboratories, Inc. devices

Submission Details

510(k) Number K772251 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received December 09, 1977
Decision Date December 22, 1977
Days to Decision 13 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
91d faster than avg
Panel avg: 104d · This submission: 13d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code CZP Iga, Antigen, Antiserum, Control
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5510
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - CZP Iga, Antigen, Antiserum, Control

All 42
Devices cleared under the same product code (CZP) and FDA review panel - the closest regulatory comparables to K772251.
LANCER L-INA ANTI-IGA
K791401 · Sherwood Medical Co. · Oct 1979
ANTISERUM, HUMAN, IGA
K790703 · Kent Laboratories, Inc. · Apr 1979
A-GENT IMMUNOGLOBULINE TEST SYSTEM
K790479 · Abbott Laboratories · Apr 1979
IMMOCHEMISTRY SYSTEM
K771603 · Beckman Instruments, Inc. · Sep 1977
GOAT ANTISERUM IGA NEPHELOMETRIC
K770962 · Kallestad Laboratories, Inc. · Jun 1977